Mounjaro is the brand name Eli Lilly uses for tirzepatide when prescribed for type 2 diabetes mellitus. The FDA approved Mounjaro in May 2022 under NDA 215866. The same molecule, tirzepatide, is marketed as Zepbound for obesity and obstructive sleep apnea. Mounjaro targets two hormonal receptors simultaneously, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which is why it falls into the dual agonist class rather than the simpler GLP-1-only category occupied by semaglutide (Ozempic, Wegovy). Clinical trials showed tirzepatide lowering HbA1c by 1.8 to 2.1 percentage points in type 2 diabetes patients.
The list price for Mounjaro is $1,079.77 per month for any dose strength, a single-flat-price model Eli Lilly has kept consistent since launch. This wholesale acquisition cost (WAC) is what retail pharmacies bill without insurance or a discount program. The actual cost a patient pays depends on their insurance status, the savings card, and whether they qualify for Lilly Cares. Unlike insulin, which has a federal $35 per month Part D cap, Mounjaro falls under the standard 2026 Medicare Part D annual out-of-pocket cap of $2,100. For Medicare coverage of GLP-1 drugs broadly, see does Medicare cover Ozempic.
Mounjaro is a self-administered subcutaneous injection given once per week via KwikPen. Because patients inject it at home, it is billed through the pharmacy benefit (Part D) rather than the medical benefit (Part B). This means there is no Medicare Part B Average Sales Price (ASP) for Mounjaro and no HCPCS J-code applies for routine outpatient use. In rare cases where tirzepatide is administered in a clinical setting, providers use the unclassified injectable drug code J3490. Most Mounjaro billing flows through retail and specialty pharmacies. Medicaid coverage of tirzepatide varies significantly by state.
What Mounjaro Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same mounjaro can cost many times more at a hospital than at your local pharmacy:
2026 Mounjaro Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail pharmacy (list price, no insurance) | $1,080/month | WAC for KwikPen, any dose 2.5 mg to 15 mg, without savings card or assistance program |
| Mounjaro Savings Card (commercially insured, T2D) | As low as $25/month | Commercially insured patients with a type 2 diabetes diagnosis; not valid with Medicare or Medicaid |
| Medicare Part D (type 2 diabetes indication) | Plan formulary copay; $2,100 annual OOP cap | Covered on most Part D plans for T2D; prior authorization typically required; not covered for weight loss |
| Medicare MFN / TrumpRx pricing (mid-2026) | $245/month; $50 copay | Trump Most Favored Nation initiative; $245 manufacturer rate to Medicare; patient pays $50 copay; rollout expected mid-2026 |
| Lilly Cares Foundation (uninsured, income-qualified) | Free (income at or below 400% FPL, approx. $63,840/individual) | Patient assistance program for uninsured; 12-month supply; must not be on Medicaid or full LIS |
| Medicaid | $1 - $8/prescription (where covered) | Coverage varies by state formulary; generally covered for type 2 diabetes management |
Mounjaro list price (WAC) is $1,079.77/month for all dose strengths as of 2026. Savings card eligibility requires commercial insurance and a type 2 diabetes diagnosis. TrumpRx MFN pricing of $245/month for Medicare is expected mid-2026 pending full implementation. GoodRx provides minimal savings off list price.
Source: Eli Lilly Mounjaro pricing, CMS Medicare Part D 2026, White House MFN fact sheet, Lilly Cares Foundation
Why Hospitals Charge So Much
Mounjaro is a self-administered outpatient drug. Patients inject it at home once per week, so it almost never appears on an inpatient hospital bill as an active treatment. When Mounjaro does appear on a hospital bill, it is almost always a continuation of a patient's outpatient regimen during a hospital admission rather than a drug being administered by hospital staff for an acute condition. In that scenario, hospitals apply their standard drug acquisition markup to whatever they paid for the pen or vial.
The more common affordability problem with Mounjaro is the gap between the retail list price ($1,080 per month) and what patients actually pay based on their insurance status. Pharmacy benefit managers (PBMs) and insurers negotiate rebates with Eli Lilly that reduce what the plan actually pays, but those negotiated savings do not automatically flow through to the patient at the pharmacy counter. Patients with high-deductible plans often pay close to the full list price until their deductible is satisfied.
For Medicare beneficiaries, the 2026 Part D cap of $2,100 provides meaningful protection for a drug at this price point. A patient filling Mounjaro for 12 months at list price would spend nearly $13,000. Under Part D, their out-of-pocket exposure stops at $2,100. After that, covered drugs cost $0 for the rest of the year. Starting mid-2026, the Trump MFN pricing initiative brings the Medicare rate to $245 per month, reducing total annual cost significantly before the OOP cap applies.
Patient Assistance Programs
Eli Lilly operates two main programs that reduce Mounjaro out-of-pocket cost: the Mounjaro Savings Card for commercially insured patients and the Lilly Cares Foundation patient assistance program (PAP) for uninsured income-qualified patients. These two programs cover different patient populations and cannot be combined with each other or with Medicare and Medicaid.
Patient assistance programs for Mounjaro| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Mounjaro Savings Card (commercially insured) | As low as $25/month for commercially insured patients with a type 2 diabetes diagnosis; not valid with Medicare, Medicaid, or TRICARE | mounjaro.lilly.com/savings |
| Lilly Cares Foundation PAP (uninsured) | Free Mounjaro for uninsured patients with income at or below 400% FPL ($63,840/year for a single person in 2026); 12-month supply; must not be on Medicaid or full LIS (Extra Help) | lillycares.com |
The Mounjaro Savings Card is for commercially insured patients only and requires a type 2 diabetes diagnosis code (ICD-10 E11.x) on the prescription. Medicare and Medicaid beneficiaries cannot use the savings card. Lilly Cares Foundation covers Mounjaro (type 2 diabetes) but does NOT cover Zepbound (obesity or OSA). Apply through lillycares.com or call 1-800-545-6962. NeedyMeds.org lists additional assistance programs.
Source: Lilly Cares Foundation, mounjaro.lilly.com/savings, NeedyMeds.org
Medicare Part D
Medicare Part D covers Mounjaro when it is prescribed for type 2 diabetes mellitus. Most Part D formularies place Mounjaro on a specialty tier (Tier 4 or 5), which carries the highest copayment percentage. Your plan may require prior authorization confirming a type 2 diabetes diagnosis (ICD-10 code E11.x), documented HbA1c levels, and sometimes prior use of metformin or another first-line agent. Part D plans do NOT cover Mounjaro when it is prescribed solely for weight management.
In 2026, the Medicare Part D annual out-of-pocket cap is $2,100. Once you have paid $2,100 in qualifying drug costs for the year, covered drugs cost $0 for the rest of the year. For a drug with a list price above $1,000 per month, this cap is a significant protection. Most patients who need Mounjaro continuously will hit the $2,100 cap within the first two to three months of the plan year.
Starting mid-2026, the Trump Most Favored Nation (MFN) pricing initiative establishes a $245 per month rate for Mounjaro under Medicare, with a patient copay of $50 per month. This represents a reduction of approximately $835 per month from the current list price. If fully implemented, Medicare patients would pay $50 per month rather than their current plan copay. Medicare beneficiaries cannot use the Mounjaro Savings Card. If your plan covers Mounjaro for type 2 diabetes and you are on Medicare, contact your State Health Insurance Assistance Program (SHIP) or call 1-800-MEDICARE for plan comparison help and updates on MFN implementation.
Common Mounjaro Billing Errors
Most Mounjaro billing errors occur at the pharmacy or in the prior authorization process rather than on a hospital bill. These are the most common problems patients encounter:
- Claim denied because the indication on file is weight loss, not type 2 diabetes: Medicare and most commercial plans require the prescription to carry an ICD-10 type 2 diabetes code (E11.x). If your prescriber entered an obesity code (E66.x) without a diabetes code, the claim will be denied. Ask your provider to add the diabetes diagnosis code to the prescription.
- Savings card rejected for Medicare or Medicaid patients: The Mounjaro Savings Card is not valid for anyone enrolled in Medicare, Medicaid, TRICARE, or any federally funded program. Attempting to use it results in a processing error at the pharmacy. Medicare patients should check for Low Income Subsidy (Extra Help) eligibility instead.
- Mounjaro billed in place of Zepbound or vice versa: Mounjaro and Zepbound are the same molecule but different products with different NDC codes and different FDA-approved indications. Billing Mounjaro when Zepbound was prescribed (or vice versa) can affect prior authorization approval and formulary tier placement. Confirm which brand name appears on both the prescription and the pharmacy claim.
- Prior authorization denied for missing clinical documentation: Most formularies require prior authorization for Mounjaro. Common denial reasons include missing HbA1c lab results, missing documentation of a prior first-line therapy trial (usually metformin), or a prescriber NPI not active on the plan. Contact your prescriber to submit the correct clinical records with the PA request.
- Patient billed at full list price despite savings card: Some pharmacies may not process the Mounjaro Savings Card correctly on the first fill. If you were charged more than $25 per month as a commercially insured patient with a T2D diagnosis, request that the pharmacist re-process the claim with the savings card, or contact Lilly directly at the number on the savings card.
Frequently Asked Questions
What is the list price for Mounjaro in 2026?
The wholesale acquisition cost (WAC) for Mounjaro KwikPen is $1,079.77 per month for any dose from 2.5 mg through 15 mg. This is the price retail pharmacies charge without insurance or a savings program. Most patients with commercial insurance pay significantly less because their plan negotiates a rebated rate, though the patient-level discount varies by plan and pharmacy benefit manager.
How do I get Mounjaro for $25 per month?
Eligible commercially insured patients with a type 2 diabetes prescription can use the Mounjaro Savings Card to pay as little as $25 per month. Eligibility requires active commercial insurance coverage and a type 2 diabetes diagnosis code (ICD-10 E11.x) on the prescription. The savings card is not valid with Medicare, Medicaid, TRICARE, or any other federally funded program. Apply at mounjaro.lilly.com/savings.
Is Mounjaro covered by Medicare Part D?
Yes, Medicare Part D covers Mounjaro when it is prescribed for type 2 diabetes mellitus. Most plans place it on a specialty tier with the highest cost-sharing percentage. Prior authorization is typically required, including documentation of a T2D diagnosis and often prior use of metformin. The 2026 Part D annual out-of-pocket cap is $2,100, after which covered drugs cost $0 for the rest of the year. Medicare does not cover Mounjaro for weight loss alone.
What is the TrumpRx MFN price for Mounjaro on Medicare?
Starting mid-2026, the Trump Most Favored Nation (MFN) pricing initiative sets Mounjaro at $245 per month for Medicare, with a $50 per month patient copay. This is a reduction from the $1,080 list price. The MFN deal was announced by the Trump administration in late 2025 after agreements with Eli Lilly and Novo Nordisk to bring US drug prices in line with prices in other developed countries. Implementation timeline is mid-2026; check with your Part D plan for enrollment details.
Is there free Mounjaro for uninsured patients?
Yes. The Lilly Cares Foundation runs a patient assistance program (PAP) for uninsured patients with income at or below 400 percent of the federal poverty level ($63,840 per year for a single person in 2026). Approved applicants typically receive a 12-month supply of Mounjaro at no cost. You must have a type 2 diabetes prescription and must not be enrolled in Medicaid or the full Low Income Subsidy (Extra Help). Apply at lillycares.com or call 1-800-545-6962.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, the same GIP/GLP-1 dual receptor agonist molecule. The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes management (approved May 2022). Zepbound is approved for chronic weight management in adults with obesity and for obstructive sleep apnea (approved November 2023 and December 2024). Coverage, prior authorization rules, and formulary placement are determined separately for each brand.
Is there a generic version of Mounjaro available?
No. As of 2026, no FDA-approved generic tirzepatide exists. Eli Lilly holds composition-of-matter patents on the tirzepatide molecule expected to run through approximately 2036. Tirzepatide is a small molecule, not a biologic, so biosimilar competition does not apply. Compounded tirzepatide was available during shortage periods but FDA enforcement tightened in 2025 as supply normalized. The savings card ($25/month with commercial insurance) or Lilly Cares PAP (free for income-qualified uninsured) are the legitimate cost-reduction options.
Will Mounjaro be subject to IRA Medicare drug price negotiation?
Mounjaro was not included in the first round of IRA Medicare drug price negotiations. The first 10 drugs with negotiated prices effective January 1, 2026 were Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and insulin aspart products (Fiasp and NovoLog). Separately, the Trump MFN initiative negotiated a $245 per month Medicare rate for Mounjaro starting mid-2026. Mounjaro may be selected in future IRA negotiation rounds as it becomes eligible based on market exclusivity timelines.
How does GoodRx affect the Mounjaro price?
GoodRx typically reduces the Mounjaro cash price to approximately $990 to $1,050 per month, which is only a minor reduction from the $1,079.77 list price. Mounjaro is a branded specialty drug with no generic competition, so GoodRx discount leverage is minimal. Uninsured patients should explore the Lilly Cares Foundation PAP (free if income-qualified at 400% FPL or below) rather than GoodRx for meaningful savings.
